# Plasma Fractionation Market Expected to Surge to $72.86 Billion by 2034

**Growing Demand Sees Market Value Increase from $35.22 Billion in 2024**

The global plasma fractionation market is on an impressive growth trajectory, projected to expand from USD 35.22 billion in 2024 to USD 72.86 billion by 2034, representing a compound annual growth rate (CAGR) of 7.54% over the decade. This significant increase highlights an intensifying demand for plasma-derived therapies and products, setting the stage for advancements in healthcare and biotechnology.

## **Key Growth Drivers Behind the Market Expansion**

The plasma fractionation market is largely driven by several key factors:

1. **Rising Incidence of Chronic Diseases:**
The prevalence of chronic and autoimmune diseases is increasing globally, creating a heightened demand for immunoglobulins and clotting factors derived from plasma.

2. **Advancements in Pharmaceutical Research:**
Continuous innovations in drug development and biopharmaceutical technologies are enhancing the efficiency of plasma fractionation processes, leading to better yields and more effective therapies.

3. **Growing Use of Plasma-Derived Therapies:**
Therapeutic plasma products like immunoglobulin, albumin, and clotting factors are becoming increasingly vital in treating various medical conditions, including hemophilia, immune deficiencies, and other rare diseases.

## **Market Segmentation and Trends**

The plasma fractionation market is segmented by product type, application, and geography:

### **1. Product Type:**
– **Immunoglobulins**
– **Albumin**
– **Clotting Factors**
– **Others**

### **2. Application:**
– **Neurology**
– **Hematology**
– **Immunology**
– **Others**

### **3. Geography:**
Regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa are expected to witness varying growth rates, with North America currently holding the largest market share due to advanced healthcare infrastructure and research capabilities.

## **The Impact of COVID-19 on the Plasma Fractionation Market**

The COVID-19 pandemic has prompted an unprecedented focus on plasma-derived therapies, especially convalescent plasma for treating the virus. This has not only accelerated research in this domain but has also fostered collaborations between healthcare organizations and research institutions, enhancing plasma collection and manufacturing efficiency.

## **Future Outlook and Conclusion**

As the plasma fractionation market continues to evolve, stakeholders are encouraged to invest in innovative technologies and strategic collaborations to capture rising opportunities. With a projected market value of USD 72.86 billion by 2034, the future appears promising for companies operating in this sector.

In summary, driven by increased demand for plasma-derived therapies and significant advancements in biopharmaceutical applications, the plasma fractionation market is poised for robust growth over the next decade.

—

*For more information on the plasma fractionation market and ongoing developments in biopharmaceuticals, stay tuned to our updates.*